Now showing items 1-6 of 6
Anti-TB Drug Leads from Diverse Natural Sources
The present study aims to demonstrate two distinct approaches to searching for leads for anti-TB drug discovery from natural products, involving the assessment of ethnomedical information (Chapters 2 and 3) and fungi ...
Secondary Metabolite Regulation And Drug-Lead Discovery From Aquatic Actinomycetes.
Chapter 1 provides an introduction to the field of natural products, drug discovery from the aquatic environment, and the development of Actinobacteria as a resource of drug-leads. Chapter 2 details one such effort that ...
Cheminformatics and Data Mining in Drug Discovery Targeting Bacterial Enoyl-ACP Reductase
The enzymes of the bacterial fatty acid biosynthetic pathway (FAS II), represent attractive targets for antimicrobial drug design, because their mammalian counterpart (FAS I) uses a single, multifunctional enzyme with low ...
Closing the In Vitro/In Vivo Gap in Tuberculosis Drug Discovery
This study establishes a new anti-M. tuberculosis (M. tb) drug lead screening scheme that integrates in vitro and in vivo methods for early detection of bioactive constituents during the purification of nature-derived ...
Antibiotics from Aquatic-Derived Actinomycete Bacteria that Inhibit M. tuberculosis
The World Health Organization (WHO) estimated that 1.5 million deaths were attributed to TB infection in 2014. Of these, 190,000 fatalities were a result of multidrug- and extensively drug-resistant strains of M. tuberculosis. ...
Identification and Characterization of Potential Drug Targets In Serous Ovarian Cancer
Ovarian cancer is the most lethal gynecological disease in women in the US. The Cancer Genome Atlas Network identified p53 mutations in 96% of high-grade serous ovarian carcinomas, demonstrating a critical role. Additionally, ...